Photo: JOHN THYS / Getty Images
The Joe Biden’s administration plans to purchase 10 million treatments from Pfizer against covid-19, a pill that promises to avoid hospitalizations and deaths for the disease.
According to a report by The Washington Post, the federal government plans to do a millionaire investment because he hopes to change the country’s outlook in the face of the pandemic.
It indicates that sources familiar with the purchase assured that the agreement could be known in the next few days.
And it is that health experts consider that both this treatment and Merck’s could join the fight that vaccines are already giving, to help walk towards normalityThese drugs work by counteracting the most pernicious effects of the virus.
Initially, The Washington Post indicates, the Biden government planned to buy five million treatments from Pfizer, but your decision changed after it was known that the drug gave results above expectations. So the president decided to double that number.
Pfizer indicated earlier this month that its experimental pill, which will be marketed under the name Paxlovid, reduced the risk of hospitalization and death by almost 90% when taken in the first three days after the onset of symptoms.
The pharmaceutical you are seeking emergency use authorization from the Food and Drug Administration (FDA) for the pill also known as PF-07321332.
He also reported a licensing agreement for access to his medicine wider, including in developing countries.
“With more than 5 million deaths and countless lives affected by this devastating disease around the world, there is an urgent need for life-saving treatment options. The overwhelming efficacy achieved in our recent Paxlovid clinical study – and its potential to help save lives and keep people out of hospital if authorized – underscores the key role of oral antiviral therapies could play in the battle against COVID-19, “said Albert Bourla, president and CEO of Pfizer, in a statement.
The signature indicates that your medication must be given with another older antiviral, ritonavir, and that the treatment is effective in treating mild to moderate COVID-19 in patients at increased risk of hospitalizations or death.
It is good news especially for two factors: the arrival of colder days and the increase in covid-19 diagnoses in approximately half of the country’s states, with an increase also in the number of hospitalizations.
This also interests you:
– Vaccinated Adults Could Soon Receive Pfizer’s Covid-19 Booster Vaccine In The United States
– Covid-19 cases skyrocket in several states of the country and fuel fears of a fifth wave
– Pfizer asks the FDA to authorize the booster dose of its vaccine against covid-19